Chemours (CC) presents a deeply negative liquidation recovery posture as of March 31, 2026. MFFAIS reports a cash liquidation value of negative $5.3B and a liquid liquidation value of negative $4.7B, reflecting the structural asymmetry between haircut-adjusted assets and face-value liabilities. Total assets of $7.3B face total liabilities of $7.1B at book, leaving book equity of only $216M — a thin buffer before any haircut is applied. Under liquidation haircuts, the asset side collapses materially: cash of $563M recovers at par, but inventory of $1.54B recovers at roughly $920M (60%), AR of $759M recovers at approximately $683M-$721M (90-95%), and PP&E net of $3.04B (gross $9.9B, accumulated depreciation $6.9B) recovers at 50-70% of net book, yielding $1.5B-$2.1B. Intangibles ($2M OtherIntangibleAssetsNet, $46M Goodwill) recover at zero. Against these haircut assets, liabilities remain at face: $4.1B long-term debt, $617M environmental remediation accrual, $491M litigation reserve (inclusive of PFAS/state settlements), $254M combined operating and finance lease obligations, and $1.6B in current liabilities. The environmental and litigation liability stack is particularly punishing in liquidation: both are non-extinguishable on wind-up and the filing discloses potential upside exposure of up to $630M above the $617M environmental accrual. The New Jersey Judicial Consent Order alone represents $266M NPV in Chemours' share of a 25-year, $875M total settlement — a cash commitment that survives any restructuring absent a court ruling. The March 2026 debt refinancing — issuance of $700M in 7.875% senior unsecured notes due 2034, concurrent redemption of $495M 5.375% notes due 2027 and $188M of 5.750% notes due 2028 — extends the maturity wall but increases gross leverage and annual cash interest by approximately $9M net. The April 2026 paydown of EUR 140M on the tranche B-3 euro term loan reduces near-term euro exposure but was funded from on-hand cash, reducing the liquidity buffer from $670M at December 31, 2025 to $563M at March 31, 2026. Moody's Ba3 with negative outlook and S&P BB- with negative outlook confirm sub-investment-grade status, relevant to any DIP or refinancing scenario. The PFAS Insurance MOU discussed in MD&A (providing up to $150M consideration to fund NJ settlement obligations) is referenced extensively but does not appear as a separately tagged XBRL asset offset in TAG_CONTEXT, limiting its measurability on the balance sheet.
▼ Community Notes